South San Francisco, CA November 16, 2017 Genentech Press Release The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the…